JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
05/11/24 - 16:27
Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)
29/07/24 - 15:55
DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)
10/05/24 - 15:21
Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)
15/03/24 - 13:35
The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)
09/11/17 - 14:15
GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)
29/09/17 - 15:00
DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)
03/08/17 - 14:45
DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)
26/06/17 - 9:45
DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)
08/05/17 - 19:30
DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)
27/04/17 - 18:45
DiaSorin - Annual General Meeting 2016 (421.04 KB)
08/03/17 - 15:30